GB201416727D0 - Use - Google Patents

Use

Info

Publication number
GB201416727D0
GB201416727D0 GBGB1416727.4A GB201416727A GB201416727D0 GB 201416727 D0 GB201416727 D0 GB 201416727D0 GB 201416727 A GB201416727 A GB 201416727A GB 201416727 D0 GB201416727 D0 GB 201416727D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1416727.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NovaBiotics Ltd
Original Assignee
NovaBiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NovaBiotics Ltd filed Critical NovaBiotics Ltd
Priority to GBGB1416727.4A priority Critical patent/GB201416727D0/en
Publication of GB201416727D0 publication Critical patent/GB201416727D0/en
Priority to PCT/GB2015/052714 priority patent/WO2016046524A1/en
Priority to AU2015323566A priority patent/AU2015323566B2/en
Priority to SG11201701648UA priority patent/SG11201701648UA/en
Priority to NZ730092A priority patent/NZ730092A/en
Priority to KR1020177008807A priority patent/KR20170052613A/en
Priority to CA2959003A priority patent/CA2959003A1/en
Priority to BR112017005272A priority patent/BR112017005272A2/en
Priority to RU2017108196A priority patent/RU2017108196A/en
Priority to EP15770619.3A priority patent/EP3197476A1/en
Priority to MX2017003550A priority patent/MX2017003550A/en
Priority to JP2017515704A priority patent/JP2017532317A/en
Priority to CN201580051064.7A priority patent/CN106687140A/en
Priority to ZA2017/01330A priority patent/ZA201701330B/en
Priority to IL251040A priority patent/IL251040A0/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1416727.4A 2014-09-22 2014-09-22 Use Ceased GB201416727D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB1416727.4A GB201416727D0 (en) 2014-09-22 2014-09-22 Use
CN201580051064.7A CN106687140A (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds
CA2959003A CA2959003A1 (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds
RU2017108196A RU2017108196A (en) 2014-09-22 2015-09-21 The use of cysteamine in the treatment of yeast / mold infection
SG11201701648UA SG11201701648UA (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds
NZ730092A NZ730092A (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds
KR1020177008807A KR20170052613A (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds
PCT/GB2015/052714 WO2016046524A1 (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds
BR112017005272A BR112017005272A2 (en) 2014-09-22 2015-09-21 cysteamine to treat yeast / mold infections
AU2015323566A AU2015323566B2 (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds
EP15770619.3A EP3197476A1 (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds
MX2017003550A MX2017003550A (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds.
JP2017515704A JP2017532317A (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeast / filamentous fungi
ZA2017/01330A ZA201701330B (en) 2014-09-22 2017-02-22 Use of cysteamine in treating infections caused by yeasts / moulds
IL251040A IL251040A0 (en) 2014-09-22 2017-03-08 Use of cysteamine in treating infections caused by yeasts/moulds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1416727.4A GB201416727D0 (en) 2014-09-22 2014-09-22 Use

Publications (1)

Publication Number Publication Date
GB201416727D0 true GB201416727D0 (en) 2014-11-05

Family

ID=51869299

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1416727.4A Ceased GB201416727D0 (en) 2014-09-22 2014-09-22 Use

Country Status (14)

Country Link
EP (1) EP3197476A1 (en)
JP (1) JP2017532317A (en)
KR (1) KR20170052613A (en)
CN (1) CN106687140A (en)
AU (1) AU2015323566B2 (en)
BR (1) BR112017005272A2 (en)
CA (1) CA2959003A1 (en)
GB (1) GB201416727D0 (en)
MX (1) MX2017003550A (en)
NZ (1) NZ730092A (en)
RU (1) RU2017108196A (en)
SG (1) SG11201701648UA (en)
WO (1) WO2016046524A1 (en)
ZA (1) ZA201701330B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018000202A (en) 2015-07-02 2018-06-27 Horizon Orphan Llc Ado-resistant cysteamine analogs and uses thereof.
JP2020505359A (en) * 2017-01-25 2020-02-20 アデア ファーマシューティカルズ,インコーポレイテッド Cysteamine prodrug
WO2018224813A1 (en) * 2017-06-06 2018-12-13 Novabiotics Limited Use of cysteamine compositions
EP3866775A1 (en) * 2018-10-17 2021-08-25 Novabiotics Limited Dosage regime
CN110551637B (en) * 2019-09-03 2020-11-27 黑龙江省农业科学院植物保护研究所 Echinospora echinocandii from radix astragali root for efficiently inhibiting botrytis cinerea and application thereof
CN110859950B (en) * 2019-11-25 2021-08-10 武汉大学 Pharmaceutical composition for candida albicans echinocandin drug-resistant bacteria and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US6086921A (en) * 1995-04-25 2000-07-11 Wintrop-University Hospital Metal/thiol biocides
ATE479704T1 (en) * 2004-08-18 2010-09-15 Novabiotics Ltd ANTIMICROBIAL PEPTIDES WITH A MOTIF CONTAINING ARGININE AND/OR LYSINE
JP2006347990A (en) * 2005-06-20 2006-12-28 Pola Chem Ind Inc Antifungal medicine composition for nail
JP2006347989A (en) * 2005-06-20 2006-12-28 Pola Chem Ind Inc Antifungal medicine composition for nail
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
EP2464334A4 (en) * 2009-08-13 2014-03-26 Moberg Derma Ab Compositions and methods for treating fungal infection of the nail
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition

Also Published As

Publication number Publication date
MX2017003550A (en) 2017-07-28
KR20170052613A (en) 2017-05-12
EP3197476A1 (en) 2017-08-02
CA2959003A1 (en) 2016-03-31
WO2016046524A1 (en) 2016-03-31
JP2017532317A (en) 2017-11-02
NZ730092A (en) 2018-05-25
AU2015323566B2 (en) 2018-03-22
AU2015323566A1 (en) 2017-04-06
RU2017108196A3 (en) 2019-06-19
RU2017108196A (en) 2018-10-24
BR112017005272A2 (en) 2017-12-12
SG11201701648UA (en) 2017-04-27
CN106687140A (en) 2017-05-17
ZA201701330B (en) 2018-04-25

Similar Documents

Publication Publication Date Title
DK3237446T3 (en) Anti-PD-1-antistoffer
DK3236972T3 (en) Antivirale N4-hydroxycytidin-derivativer
DK3373003T3 (en) Urinteststrimmel
AU361515S (en) Dishrack
AU362944S (en) Lapboard
GB201412290D0 (en) Novel use
GB201403944D0 (en) New use
DK3191586T3 (en) Cellobiosephosphorylase
DK3178931T3 (en) Anti-orai1-antistof
GB201416727D0 (en) Use
GB201416716D0 (en) Use
DK3002465T3 (en) Hydrauliksystem
GB201417497D0 (en) Novel use
DK3234061T3 (en) Nano-inhibitorer
GB201420095D0 (en) New use
DK3194944T3 (en) Tomografiapparat
DK3145380T3 (en) Toiletventilationssystem
GB201417499D0 (en) Novel use
AU5594P (en) Lanoregon Mandevilla sanderi
AU5585P (en) Lanutah Mandevilla sanderi
AU5598P (en) Lanidaho Mandevilla sanderi
AU5593P (en) Lanmissouri Mandevilla sanderi
AU5597P (en) Lancalifornia Mandevilla sanderi
AU5584P (en) Laniowa Mandevilla sanderi
AU5596P (en) Lannevada Mandevilla sanderi

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)